Physician profile
Wesley D Head
NPI 1487657508
$1,629.43
in general payments reported to CMS, 2019-2025
12 companies · $342 in 2025
The $342 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74.38 · 2020: $94.33 · 2021: $131 · 2022: $242 · 2023: $349 · 2024: $396 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $970 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $969.89 |
| Education | $117.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $585.42 | 2020-2023 | Nucala |
| Astrazeneca Pharmaceuticals LP | $356.83 | 2022-2024 | Tezspire, Airsupra |
| Inspire Medical Systems, INC. | $186.10 | 2025 | Inspire |
| United Therapeutics Corporation | $124.99 | 2024 | Tyvaso |
| Lilly USA, LLC | $115.10 | 2025 | Zepbound |
| Sanofi-Aventis U.S. LLC | $99.95 | 2024 | |
| Genentech USA, INC. | $39.95 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.43 | 2019 | |
| Baxter Healthcare | $23.28 | 2025 | Hillrom - Volara System |
| Zoll Respicardia, INC. | $23.13 | 2024 | Remede System |
| Laborie Medical Technologies Corp. | $22.87 | 2024 | Endosheath Technology |
| Insmed, INC. | $17.38 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wesley Head listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.